BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Multiple Dose Japanese Bridging Study
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT01057030
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 837
- Registration Number
- NCT01057810
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Md Anderson Cancer Center Orlando, Orlando, Florida, United States
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 43
- Registration Number
- NCT01051414
- Locations
- 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan
Single Ascending Dose (BMS-813160) Study
- Conditions
- Accelerated Intimal Hyperplasia
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01049165
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
- Conditions
- Gastro-Intestinal Cancer
- Interventions
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT01046864
- Locations
- 🇺🇸
Scott & White Memorial Hospital And Clinic, Temple, Texas, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT01046422
- Locations
- 🇺🇸
Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States
🇺🇸Marina Raikhel, Md, Lomita, California, United States
🇰🇷Local Institution, Suwon, Korea, Republic of
Drug-Drug Interaction Study With Aricept® (Donepezil)
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01042314
- Locations
- 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01039194
- Locations
- 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT01037166
- Locations
- 🇯🇵
Local Institution, Kyoto, Japan
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 282
- Registration Number
- NCT01037062
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan